Country Reports on Practical Aspects of Conducting Large-Scale Community Studies of the Tolerability of Mass Drug Administration with Ivermectin/Diethylcarbamazine/Albendazole for Lymphatic Filariasis

Purushothaman Jambulingam, Swaminathan Subramanian, Kaliannagounder Krishnamoorthy, Taniawati Supali, Peter Fischer, Christine Dubray, Carl Fayette, Jean Frantz Lemoine, Moses Laman, Christopher King, Josaia Samuela, Myra Hardy, Gary J. Weil

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

This article is a compilation of summaries prepared by lead investigators for large-scale safety and efficacy studies on mass drug administration of IDA (ivermectin, diethylcarbamazine, and albendazole) for lymphatic filariasis. The summaries highlight the experiences of study teams that assessed the safety and efficacy of IDA in five countries: India, Indonesia, Haiti, Papua New Guinea, and Fiji. They also highlight significant challenges encountered during these community studies and responses to those challenges that contributed to success.

Original languageEnglish
Pages (from-to)18-25
Number of pages8
JournalThe American journal of tropical medicine and hygiene
Volume106
Issue number5
DOIs
Publication statusPublished - 11 May 2022

Fingerprint

Dive into the research topics of 'Country Reports on Practical Aspects of Conducting Large-Scale Community Studies of the Tolerability of Mass Drug Administration with Ivermectin/Diethylcarbamazine/Albendazole for Lymphatic Filariasis'. Together they form a unique fingerprint.

Cite this